+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Erleada Market Size, Share & Trends Analysis Report By Type (Branded, Generic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2025 - 2033

  • PDF Icon

    Report

  • 150 Pages
  • July 2025
  • Region: Global
  • Grand View Research
  • ID: 6154684
Description Jump to:
The global erleada market size was estimated at USD 2.99 billion in 2024 and is projected to reach USD 6.16 billion by 2033, growing at a CAGR of 7.99% from 2025 to 2033. The erleada industry is increasingly shaped by the push toward combination therapies to enhance treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC).

Phase 3 trials, such as NCT02257736, set to conclude in 2027, are evaluating Apalutamide alongside Abiraterone acetate and Prednisone to establish synergistic effects and potentially expand indications. By leveraging clinical data, like the SPARTAN trial’s 70% reduction in metastasis risk (HR 0.28), stakeholders can strengthen payer negotiations and maintain market traction. The emphasis on combination therapies strengthens Erleada’s position against emerging generics, like Zydus Lifesciences’ Apalutamide Tablets, which received USFDA approval in March 2025, threatening Erleada’s market exclusivity. Johnson & Johnson’s patents, covering specific formulations until 2038, offer legal protection, but the potential for litigation remains a concern.

The market is influenced by the growing adoption of value-based care, particularly among U.S. payers like Medicare, who favor therapies with proven long-term benefits. Erleada’s clinical evidence, including TITAN’s 33% mortality risk reduction (HR 0.67), has driven real-world impact, with Medicare Advantage plans reporting a 10% reduction in nmCRPC patient hospitalizations in 2024 compared to alternatives. Stakeholders can enhance market resilience by generating real-world evidence to demonstrate cost-effectiveness and investing in healthcare provider education on Apalutamide’s administration to boost adoption and mitigate the impact of generic competition.

The erleada industry benefits from keen awareness of early prostate cancer screening, supported by initiatives like those from the U.S. Preventive Services Task Force, which have increased diagnosis rates and expanded the eligible patient pool. This trend, coupled with Erleada’s targeted mechanism, aligns with the shift toward precision medicine, offering opportunities to address unmet needs. For instance, the 2023 approval of a 240 mg once-daily tablet improved patient compliance, reinforcing Erleada’s competitive positioning. Stakeholders should focus on leveraging these advancements to maintain market leadership amidst evolving treatment paradigms.

Global Erleada Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global erleada market report based on type, distribution channel, and region:

Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Branded
  • Generic

Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Erleada Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Erleada Market: Type Business Analysis
4.1. Type Market Share, 2024 & 2033
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. Branded
4.4.1. Branded Market, 2021 - 2033 (USD Million)
4.5. Generic
4.5.1. Generic Market, 2021 - 2033 (USD Million)
Chapter 5. Erleada Market: Distribution Channel Business Analysis
5.1. Distribution Channel Market Share, 2024 & 2033
5.2. Distribution Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
5.4. Hospital Pharmacies
5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
5.5. Retail Pharmacies
5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
5.6. Others
5.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. Erleada Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
6.4. North America
6.4.1. North America Erleada Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. U.S. Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. Canada Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. Mexico Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Europe
6.5.1. Europe Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. UK Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. Germany Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. France Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Italy Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Target Disease Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. Spain Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Target Disease Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Denmark Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Target Disease Prevalence
6.5.8.3. Regulatory Framework
6.5.8.4. Reimbursement Framework
6.5.8.5. Sweden Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Target Disease Prevalence
6.5.9.3. Regulatory Framework
6.5.9.4. Reimbursement Framework
6.5.9.5. Norway Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. India Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Australia Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Framework
6.6.6.5. South Korea Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Target Disease Prevalence
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Framework
6.6.7.5. Thailand Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Latin America
6.7.1. Latin America Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Target Disease Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. Brazil Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. Argentina Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Target Disease Prevalence
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Framework
6.8.2.5. South Africa Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Target Disease Prevalence
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Framework
6.8.3.5. Saudi Arabia Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Target Disease Prevalence
6.8.4.3. Regulatory Framework
6.8.4.4. Reimbursement Framework
6.8.4.5. UAE Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Target Disease Prevalence
6.8.5.3. Regulatory Framework
6.8.5.4. Reimbursement Framework
6.8.5.5. Kuwait Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Janssen Biotech, Inc.
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Zydus Lifesciences
7.6.1.1. Overview
7.6.1.2. Financial Performance
7.6.1.3. Product Benchmarking
7.6.1.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Erleada market, by region, 2021 - 2033 (USD Million)
Table 4 Global Erleada market, by Type, 2021 - 2033 (USD Million)
Table 5 Global Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 6 North America Erleada market, by country, 2021 - 2033 (USD Million)
Table 7 North America Erleada market, by Type, 2021 - 2033 (USD Million)
Table 8 North America Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 9 U.S. Erleada market, by Type, 2021 - 2033 (USD Million)
Table 10 U.S. Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 11 Canada Erleada market, by Type, 2021 - 2033 (USD Million)
Table 12 Canada Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 13 Mexico Erleada market, by Type, 2021 - 2033 (USD Million)
Table 14 Mexico Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 15 Europe Erleada market, by country, 2021 - 2033 (USD Million)
Table 16 Europe Erleada market, by Type, 2021 - 2033 (USD Million)
Table 17 Europe Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 18 UK Erleada market, by Type, 2021 - 2033 (USD Million)
Table 19 UK Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 20 Germany Erleada market, by Type, 2021 - 2033 (USD Million)
Table 21 Germany Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 22 France Erleada market, by Type, 2021 - 2033 (USD Million)
Table 23 France Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 24 Italy Erleada market, by Type, 2021 - 2033 (USD Million)
Table 25 Italy Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 26 Spain Erleada market, by Type, 2021 - 2033 (USD Million)
Table 27 Spain Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 28 Norway Erleada market, by Type, 2021 - 2033 (USD Million)
Table 29 Norway Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 30 Denmark Erleada market, by Type, 2021 - 2033 (USD Million)
Table 31 Denmark Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 32 Sweden Erleada market, by Type, 2021 - 2033 (USD Million)
Table 33 Sweden Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 34 Asia Pacific Erleada market, by country, 2021 - 2033 (USD Million)
Table 35 Asia Pacific Erleada market, by Type, 2021 - 2033 (USD Million)
Table 36 Asia Pacific Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 37 Japan Erleada market, by Type, 2021 - 2033 (USD Million)
Table 38 Japan Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 39 China Erleada market, by Type, 2021 - 2033 (USD Million)
Table 40 China Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 41 India Erleada market, by Type, 2021 - 2033 (USD Million)
Table 42 India Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 43 Australia Erleada market, by Type, 2021 - 2033 (USD Million)
Table 44 Australia Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 45 South Korea Erleada market, by Type, 2021 - 2033 (USD Million)
Table 46 South Korea Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 47 Thailand Erleada market, by Type, 2021 - 2033 (USD Million)
Table 48 Thailand Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 49 Latin America Erleada market, by country, 2021 - 2033 (USD Million)
Table 50 Latin America Erleada market, by Type, 2021 - 2033 (USD Million)
Table 51 Latin America Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 52 Brazil Erleada market, by Type, 2021 - 2033 (USD Million)
Table 53 Brazil Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 54 Argentina Erleada market, by Type, 2021 - 2033 (USD Million)
Table 55 Argentina Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 56 Middle East & Africa Erleada market, by country, 2021 - 2033 (USD Million)
Table 57 Middle East & Africa Erleada market, by Type, 2021 - 2033 (USD Million)
Table 58 Middle East & Africa Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 59 South Africa Erleada market, by Type, 2021 - 2033 (USD Million)
Table 60 South Africa Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 61 Saudi Arabia Erleada market, by Type, 2021 - 2033 (USD Million)
Table 62 Saudi Arabia Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 63 UAE Erleada market, by Type, 2021 - 2033 (USD Million)
Table 64 UAE Erleada market, by distribution channel, 2021 - 2033 (USD Million)
Table 65 Kuwait Erleada market, by Type, 2021 - 2033 (USD Million)
Table 66 Kuwait Erleada market, by distribution channel, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Erleada market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and application outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Erleada market dynamics
Fig. 12 Erleada market: Porter’s five forces analysis
Fig. 13 Erleada market: PESTLE analysis
Fig. 14 Type market, 2021 - 2033 (USD Million)
Fig. 15 Branded market, 2021 - 2033 (USD Million)
Fig. 16 Generic market, 2021 - 2033 (USD Million)
Fig. 17 Distribution Channel market, 2021 - 2033 (USD Million)
Fig. 18 Hospital Pharmacies market, 2021 - 2033 (USD Million)
Fig. 19 Retail Pharmacies market, 2021 - 2033 (USD Million)
Fig. 20 Others market, 2021 - 2033 (USD Million)
Fig. 21 Erleada market revenue, by region
Fig. 22 Regional marketplace: Key takeaways
Fig. 23 North America Erleada market, 2021 - 2033 (USD Million)
Fig. 24 US country dynamics
Fig. 25 US Erleada market, 2021 - 2033 (USD Million)
Fig. 26 Canada country dynamics
Fig. 27 Canada Erleada market, 2021 - 2033 (USD Million)
Fig. 28 Mexico country dynamics
Fig. 29 Mexico Erleada market, 2021 - 2033 (USD Million)
Fig. 30 Europe Erleada market, 2021 - 2033 (USD Million)
Fig. 31 UK country dynamics
Fig. 32 UK Erleada market, 2021 - 2033 (USD Million)
Fig. 33 Germany country dynamics
Fig. 34 Germany Erleada market, 2021 - 2033 (USD Million)
Fig. 35 France country dynamics
Fig. 36 France Erleada market, 2021 - 2033 (USD Million)
Fig. 37 Italy country dynamics
Fig. 38 Italy Erleada market, 2021 - 2033 (USD Million)
Fig. 39 Spain country dynamics
Fig. 40 Spain Erleada market, 2021 - 2033 (USD Million)
Fig. 41 Norway country dynamics
Fig. 42 Norway Erleada market, 2021 - 2033 (USD Million)
Fig. 43 Sweden country dynamics
Fig. 44 Sweden Erleada market, 2021 - 2033 (USD Million)
Fig. 45 Denmark country dynamics
Fig. 46 Denmark Erleada market, 2021 - 2033 (USD Million)
Fig. 47 Asia Pacific Erleada market, 2021 - 2033 (USD Million)
Fig. 48 Japan country dynamics
Fig. 49 Japan Erleada market, 2021 - 2033 (USD Million)
Fig. 50 China country dynamics
Fig. 51 China Erleada market, 2021 - 2033 (USD Million)
Fig. 52 India country dynamics
Fig. 53 India Erleada market, 2021 - 2033 (USD Million)
Fig. 54 Australia country dynamics
Fig. 55 Australia Erleada market, 2021 - 2033 (USD Million)
Fig. 56 South Korea country dynamics
Fig. 57 South Korea Erleada market, 2021 - 2033 (USD Million)
Fig. 58 Thailand country dynamics
Fig. 59 Thailand Erleada market, 2021 - 2033 (USD Million)
Fig. 60 Latin America Erleada market, 2021 - 2033 (USD Million)
Fig. 61 Brazil country dynamics
Fig. 62 Brazil Erleada market, 2021 - 2033 (USD Million)
Fig. 63 Argentina country dynamics
Fig. 64 Argentina Erleada market, 2021 - 2033 (USD Million)
Fig. 65 MEA Erleada market, 2021 - 2033 (USD Million)
Fig. 66 South Africa country dynamics
Fig. 67 South Africa Erleada market, 2021 - 2033 (USD Million)
Fig. 68 Saudi Arabia country dynamics
Fig. 69 Saudi Arabia Erleada market, 2021 - 2033 (USD Million)
Fig. 70 UAE country dynamics
Fig. 71 UAE Erleada market, 2021 - 2033 (USD Million)
Fig. 72 Kuwait country dynamics
Fig. 73 Kuwait Erleada market, 2021 - 2033 (USD Million)
Fig. 74 Company categorization
Fig. 75 Company market position analysis
Fig. 76 Strategic framework

Companies Mentioned

  • Janssen Biotech, Inc.
  • Zydus Lifesciences

Related Topics

Related Reports

U.S. Erleada Market Size, Share & Trends Analysis Report By Type (Branded, Generic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), And Segment Forecasts, Key Companies, And Competitive Analysis, 2025 - 2033 - Product Image

U.S. Erleada Market Size, Share & Trends Analysis Report By Type (Branded, Generic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), And Segment Forecasts, Key Companies, And Competitive Analysis, 2025 - 2033

  • Report
  • 120 Pages
  • United States
From
Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032 - Product Image

Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • 432 Pages
  • Global
From
Non-metastatic Prostate Cancer (nmPC) - Market Insight, Epidemiology and Market Forecast -2032 - Product Image

Non-metastatic Prostate Cancer (nmPC) - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • 230 Pages
  • Global
From
Androgen Deprivation Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Androgen Deprivation Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 110 Pages
  • Global
From
Non-metastatic Prostate Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035 - Product Image

Non-metastatic Prostate Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.